Artificial, Humanized Stem Cell Niches

人工、人性化干细胞生态位

• 批准号: 10192715
• 负责人: Biju Parekkadan
• 金额: $ 54.22万
• 依托单位: RUTGERS, THE STATE UNIV OF N.J.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10192715
• 关键词: 3-Dimensional; Anatomy; Area; Biopsy; Biopsy Specimen; Bioreactors; Blood Vessels; Bone Marrow; Bone Marrow Cells; Bone Marrow Diseases; Bone Marrow Stem Cell; Bone marrow biopsy; Cell Adhesion Molecules; Cell Line; Cells; Clinical; Clinical Trials; Companions; Cultured Cells; Custom; Diagnostic; Discontinuous Capillary; Disease; Disease Progression; Dysmyelopoietic Syndromes; Endothelium; Engineering; Engraftment; Environment; Exposure to; Extracellular Matrix; Freezing; Future; Generations; Genetic Engineering; Goals; Grant; Growth; Growth Factor; Hematology; Hematopoietic stem cells; Human; Implant; Incidence; Institution; Intuition; Lesion; Letters; Liquid substance; Longitudinal Studies; Malignant Neoplasms; Marrow; Measures; Mechanics; Methods; Microfluidics; Modeling; Mus; Oncology; Outcome; Patient-Focused Outcomes; Patients; Perfusion; Pharmaceutical Preparations; Property; Protocols documentation; Recreation; Research; Risk; Sampling; Standardization; Stromal Cells; Structure; System; Technology; Testing; Tissue Engineering; Tissue Sample; Tissues; Variant; Vision; Xenograft Model; Xenograft procedure; bone; bone engineering; cancer stem cell; cell bank; cellular engineering; chemotherapy; cytokine; cytopenia; design; environmental enrichment for laboratory animals; fluid flow; genetically modified cells; hematopoietic stem cell expansion; hematopoietic stem cell self-renewal; hydrogel scaffold; individual patient; innovation; leukemia; leukemic transformation; miniaturize; next generation; novel strategies; osteoprogenitor cell; overexpression; progenitor; prognostic; prognostic value; prospective; risk stratification; scaffold; stem cell niche; stem cells; translational research program; tumor microenvironment

Abstract This project will develop and verify a microtissue engineered bioreactor platform to expand bone marrow cancer stem cells and create xenograft models using frozen MDS patient marrow cells. The project specific aims are: (1) Specific Aim 1: Microfluidic bioreactor for human HSC expansion from a low volume marrow sample; (2) Specific Aim 2: Genetically engineered scaffolds to recreate a MDS microenvironment ex vivo; and (3) Specific Aim 3: Ex vivo differentiation testing of MDS stem cells to predict leukemic transformation. The deliverable of the project will be a qualified bioreactor culture system and protocol to expand rare cells, such as pre-leukemic stem cells, from a small volume bone marrow biopsy tissue sample for use in prospective clinical trials.

摘要